Venlafaxine: Side Effects, Uses & Monitoring

Facts extracted from current FDA product labeling for Venlafaxine. Educational only — not medical advice.

Reported adverse reactions

ReactionHighest frequency reported*
Abnormal ejaculation16%
Nausea8%
Constipation8%
Diarrhea8%
Pharyngitis7%
Dyspepsia7%
Abdominal pain6%
Anxiety5%
Hypertension4%
Flatulence4%
Accidental injury4%
Asthenia3%
Insomnia3%
Somnolence3%
Weight loss3%
Depression3%
Paresthesia3%
Libido decreased3%
Agitation3%
Yawn3%

*Highest percentage across placebo-controlled trial tables summarized in current labeling.

Labeled uses

Major Depressive Disorder Venlafaxine hydrochloride extended-release capsules are indicated for the treatment of major depressive disorder. The efficacy of venlafaxine hydrochloride extended-release capsules in the treatment of major depressive disorder was established in 8- and 12-week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III-R or DSM-IV category of major depressive disorder (see Clinical Trials ). A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed mood or the loss of interest or pleasure in nearly all activities, representing a change from previous functioning, and includes the presence of at least five of the following nine symptoms during the same two-week period: depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. The efficacy of venlafaxine hydrochloride tablets (immediate r…

Source: FDA labeling via NIH DailyMed (set 3cfc589e…). Not affiliated with FDA or NIH.

Medical disclaimer: Always consult a qualified healthcare professional about any medication.